
Sarah A Myers MD
Professor Dermatology, Duke University School of Medicine
Join to view full profile
2100 Erwin RdDurham, NC 27705
Phone+1 919-620-4467
Dr. Myers is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified dermatologist specializing in complex medical dermatology, specifically the care of immunocompromised patients from solid organ transplant.
Education & Training
Duke University HospitalResidency, Dermatology, 1990 - 1993
Duke University HospitalInternship, Internal Medicine, 1989 - 1990
Duke University School of MedicineClass of 1989
Certifications & Licensure
NC State Medical License 1991 - 2027
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- Paradoxical development of reactive squamous atypia and aggressive, invasive squamous cell carcinoma following 5-fluorouracil for field cancerization with concurrent i...Erik Jaklitsch, Lauren D Crow, Amy Petty, Edgar Martinez, Melodi J Whitley
Clinical and Experimental Dermatology. 2025-07-24 - 4 citationsRecognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.Emma L Myers, Jessica Liu, Sabrina M Shearer, Sarah A Myers, Michelle Schneider
JAAD Case Reports. 2025-04-01 - 9 citationsDe novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.Olivia S Jew, Winston W Liu, Christopher Stamey, Meenal Kheterpal, Sarah A Myers
Journal of the American Academy of Dermatology. 2024-10-01
Press Mentions
New Mothers Twice as Likely to Have Post-Natal Depression in LockdownMay 11th, 2021
Who Cares for Women with Children? Crossing the Bridge Between DisciplinesMay 3rd, 2021
2020 TOGO Awards Recognize Community as ‘A Place of Heart’November 23rd, 2020
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: